MGTXMeiraGTx Holdings plc
Biological Products, (no Diagnostic Substances)
- Revenue
- $81M
- 145% YoY
- Operating margin
- -130.2%
- 74% YoY
- EBITDA
- −$93M
- 38% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired27% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $38M | $16M | $14M | $33M | $81M | 145% |
| Operating income | −$73M | −$116M | −$137M | −$164M | −$106M | 35% |
| Net income | −$80M | −$130M | −$84M | −$148M | −$114M | 23% |
| Operating cash flow | −$11M | −$73M | −$105M | −$104M | −$46M | 56% |
| Capex | $46M | $45M | $20M | $5M | $4M | 23% |
| Stock-based comp | $21M | $29M | $28M | $25M | $22M | 12% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $851K · 2
- Net
- −$851K
Pay vs performance
No pay-versus-performance disclosure yet.